Video

Ibrutinib-Rituximab and Venetoclax (IRV) Followed by Risk-Stratified R-HyperCVAD/MTX in Young Patients With Untreated Mantle Cell Lymphoma – Phase-II WINDOW-2 Trial

Author(s):

Michael Wang, MD

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
the α-CORRECT study
Julie M. Vose, MD, MBA
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
AGAVE-201
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Carrie L. Kitko, MD
Peter Riedell, MD
Related Content
Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
March 13th 2025

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Cema-Cel in R/R LBCL | Image Credit: © LASZLO – stock.adobe.com
March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Image credit: © Fotograf – stock.adobe.com
March 6th 2025

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL

Ivosidenib/CPX-351 in IDH1-Mutated AML and MDS | Image credit: © Maris – stock.adobe.com
March 4th 2025

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS